(NASDAQ: AUTL) Autolus Therapeutics's forecast annual revenue growth rate of 368.18% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.32%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.27%.
Autolus Therapeutics's revenue in 2024 is $1,698,000.On average, 4 Wall Street analysts forecast AUTL's revenue for 2024 to be $7,356,585,302, with the lowest AUTL revenue forecast at $37,229,683, and the highest AUTL revenue forecast at $15,218,430,583. On average, 4 Wall Street analysts forecast AUTL's revenue for 2025 to be $18,466,188,546, with the lowest AUTL revenue forecast at $10,432,288,945, and the highest AUTL revenue forecast at $29,118,930,398.
In 2026, AUTL is forecast to generate $49,691,255,279 in revenue, with the lowest revenue forecast at $36,596,778,094 and the highest revenue forecast at $72,044,754,551.